Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria

International Journal of Dermatology

Volumn 45, Issue 4, 2006, Pages 394-396

  Cassano, Nicoletta ^a,b   Raho, Gabriella ^a,b   Filieri, Maura ^a,b   D'Argento, Vito ^a,b   Amoruso, Antonella ^a,b   Filotico, Raffaele ^a,b   Vena, Gino A ^a,b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DESLORATADINE; FLUORESCEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; XANTHINE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CHRONIC URTICARIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; IDIOPATHIC DISEASE; IN VIVO STUDY; MALE; OXIDATIVE STRESS; SPECTROFLUOROMETRY; THROMBOCYTE; VOLUNTEER;

ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SEVERITY OF ILLNESS INDEX; SUPEROXIDE DISMUTASE; URTICARIA;

EID: 33645548694     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02467.x     Document Type: Article

References (18)

1. Assanasen P, Naclerio RM. Antiallergic anti-inflammatory effects of H1-antihistamines in humans. Clin Allergy Immunol 2002; 17: 101-139.
2. Ciprandi G, Passalacqua G, Canonica GW. Effects of H1 antihistamines on adhesion molecules: A possible rationale for long-term treatment. Clin Exp Allergy 1999; 29: 49-53.
3. Cassano N, Amoruso A, Nettis E, et al. Attivitàbiologica dell'istamina e profilo farmacologico degli antistaminici usati in dermatologia. Ann Ital Dermatol Allergol 2000; 54: 121-134.
4. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107: 751-762.
5. Briganti S, Cristaudo A, D'Argento V, et al. Oxidative stress in physical urticarias. Clin Exp Dermatol 2001; 26: 284-288.
6. Raho G, Cassano N, D'Argento V, et al. Over-expression of Mn-superoxide dismutase as a marker of oxidative stress in lesional skin of chronic idiopathic urticaria. Clin Exp Dermatol 2003; 28: 318-320.
7. Cassano N, Raho G, Filieri M, et al. Valutazione di markers di stress ossidativo nel plasma di pazienti con orticaria cronica idiopatica. Ann Ital Dermatol Allergol 2003; 57: 64-68.
8. Leoncini G, Maresca M, Buzzi E, et al. Platelets of patients affected with essential thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur J Haemat 1990; 44: 116-120.
9. Maresca M, Colao C, Leoncini G. Generation of hydrogen proxide in resting and activated platelets. Cell Biochem Funct 1992; 10: 79-85.
10. Niwa Y, Kanoh T, Sakane T, et al. The ratio of lipid peroxides to superoxide dismutase activity in the skin lesions of patients with severe skin diseases. An accurate prognostic indicator. Life Sci 1987; 40: 921-927.
11. Yoshimaru T, Suzuki Y, Matsui T, et al. Blockade of superoxide generation prevents high-affinity immunoglobulin E receptor-mediated release of allergic mediators by rat mast cell line and human basophils. Clin Exp Allergy 2002; 32: 612-618.
12. Wolfreys K, Oliveira DB. Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol 1997; 27: 297-306.
13. Santos FX, Arroyo C, Garcia I, et al. Role of mast cells in the pathogenesis of postburn inflammatory response: Reactive oxygen species as mast cell stimulators. Burns 2000; 26: 145-147.
14. Fuchs J. Oxidative Injury in Dermatopathology. Berlin: Springer-Verlag, 1992.
15. Lontz W, Sirsjo A, Liu W, et al. Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha. Free Radic Biol Med 1995; 18: 349-355.
16. Murdoch D, Goa KL, Keam SJ. Desloratadine: An update of its efficacy in the management of allergic disorders. Drugs 2003; 63: 2051-2077.
17. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40: 72-76.
18. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003; 48: 535-541.